Quercetin as a Novel Therapeutic Approach for Lymphoma.
Saved in:
| Title: | Quercetin as a Novel Therapeutic Approach for Lymphoma. |
|---|---|
| Authors: | Soofiyani SR; Clinical Research Development Unit of Sina Educational, Research, and Treatment Center, Tabriz University of Medical Sciences, Tabriz, Iran., Hosseini K; Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.; Department of Molecular Medicine, Faculty of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran., Forouhandeh H; Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran., Ghasemnejad T; Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran., Tarhriz V; Molecular Medicine Research Center, Biomedicine Institute, Tabriz University of Medical Sciences, Tabriz, Iran., Asgharian P; Department of Pharmacognosy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran., Reiner Ž; Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia., Sharifi-Rad J; Phytochemistry Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran., Cho WC; Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong. |
| Source: | Oxidative medicine and cellular longevity [Oxid Med Cell Longev] 2021 Aug 02; Vol. 2021, pp. 3157867. Date of Electronic Publication: 2021 Aug 02 (Print Publication: 2021). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101479826 Publication Model: eCollection Cited Medium: Internet ISSN: 1942-0994 (Electronic) Linking ISSN: 19420994 NLM ISO Abbreviation: Oxid Med Cell Longev Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
